2269:HKG
WuXi Biologics (Cayman) Inc
48,20Â HK$
arrow_downward
-0,90%(-0,44) 1D
16 tet, 4:08:14 m.d., GMT+8 · HKD
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për 2269...
Hap
49,98Â HK$
I lartë
50,85Â HK$
I ulët
45,82Â HK$
Kapitalizimi i tregut
198,43Â mld
Vëllimi mesatar
30,42Â mln
Vëllimi
55,18Â mln
Raporti çmim/fitim
34,48
Maksimumi 52-javor
58,00Â HK$
Minimumi 52-javor
28,48Â HK$
Fitimet për aksion
1,40Â HK$
Aksionet në qarkullim
1,23Â mld
Numri i punonjësve
15 mijë
Hap
49,98Â HK$
I lartë
50,85Â HK$
I ulët
45,82Â HK$
Kapitalizimi i tregut
198,43Â mld
Vëllimi mesatar
30,42Â mln
Vëllimi
55,18Â mln
Raporti çmim/fitim
34,48
Maksimumi 52-javor
58,00Â HK$
Minimumi 52-javor
28,48Â HK$
Fitimet për aksion
1,40Â HK$
Aksionet në qarkullim
1,23Â mld
Numri i punonjësve
15 mijë
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
AskTraders.com
·
1 orë më parë
S&P 500 Can Absorb Fed Hikes, Says UBS CIO After Hot US Inflation
Traders Union
·
1 orë më parë
Peter Tuchman: Nasdaq posts worst week since April 2025 tariff selloff as S&P 500 loses $1.3 trillion
Yahoo Finance
·
10 orë më parë
Michael Burry Warns of a Stock Market ‘Supervolcano’
AOL.com
·
6 orë më parë
Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors.
Profili
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Rreth WuXi Biologics (Cayman) Inc
Drejtori ekzekutivZhisheng Chen
Punonjësit14,7 mijë
Themeluar më2010
Selia-
SektoriHealth care
Uebsajtiwuxibiologics.com